Literature DB >> 29468061

Plasma interleukin-8 levels are persistently elevated for 1 month after minimally invasive colorectal resection for colorectal cancer.

H M C Shantha Kumara1, Elli Sutton1, Geoffrey A Bellini1, Xiaohong Yan1, Vesna Cekic1, Nipa Dilip Gandhi1, Richard L Whelan1,2.   

Abstract

Minimally invasive colorectal resection (MICR) for colorectal cancer (CRC) is associated with elevated levels of seven proangiogenic proteins that persist for 2-4 weeks after surgery. The proangiogenic plasma may promote tumor growth postoperatively in patients with residual cancer. To the best of our knowledge, the impact of surgery on interleukin 8 (IL-8) levels is unknown. The aim of the present study was to evaluate plasma IL-8 levels after MICR for CRC. Patients with CRC enrolled in an institutional review board-approved plasma/data bank who underwent MICR were eligible. Blood samples were taken preoperatively (preop) and at multiple postoperative (postop) time points, and were stored at -80°C. Only patients for whom preop, postop day (POD) 1, POD 3 and at least 1 late postop plasma samples (POD7-34) available were enrolled. Clinical, demographical and pathological data were collected. IL-8 levels were determined via ELISA and results were reported as the mean and ± standard deviation. The Wilcoxon signed rank test was used for analysis with P<0.05 used as the significance threshold. A total of 73 CRC patients (colon, 62%; rectal, 38%) who underwent MICR (laparoscopic-assisted, 60%; hand-assisted, 40%) were studied. The mean preop IL-8 level was 20.4±10.6 pg/ml. Significant elevations in plasma IL-8 levels were noted compared with preop levels on POD1 (43.1±38.6; n=72; P<0.0001), POD 3 (33.0±30.1; n=71; P<0.0001), POD7-13 (29.9±21.9; n=50; P<0.0001), POD14-20 (33.1±18.3; n=24; P=0.002), and for the POD21-27 time point (24.0±9.2; n=16; P=0.002). In conclusion, plasma IL-8 levels were significantly elevated from baseline for 4 weeks after MICR for CRC. In conjunction with the other proangiogenic MICR-associated blood compositional changes, increased IL-8 levels may promote tumor angiogenesis and growth postop.

Entities:  

Keywords:  minimally invasive colorectal resection; plasma interleukin-8

Year:  2017        PMID: 29468061      PMCID: PMC5791423          DOI: 10.3892/mco.2017.1538

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  37 in total

1.  Experimental evidence in support of the dormant tumor cell.

Authors:  B FISHER; E R FISHER
Journal:  Science       Date:  1959-10-09       Impact factor: 47.728

2.  Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.

Authors:  Aihua Li; Michelle L Varney; Jason Valasek; Maurice Godfrey; Bhavana J Dave; Rakesh K Singh
Journal:  Angiogenesis       Date:  2005       Impact factor: 9.596

Review 3.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

4.  Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin.

Authors:  M Sticherling; E Bornscheuer; J M Schröder; E Christophers
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

5.  Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells.

Authors:  A M Eggermont; E P Steller; R L Marquet; J Jeekel; P H Sugarbaker
Journal:  Cancer Detect Prev       Date:  1988

6.  Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; David Gaita; Hiromichi Miyagaki; Xiaohong Yan; Sonali Ac Hearth; Linda Njoh; Vesna Cekic; Richard L Whelan
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

7.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

8.  Influence of interleukin-8 (IL-8) and IL-8 receptors on the migration of human keratinocytes, the role of PLC-γ and potential clinical implications.

Authors:  Wen G Jiang; Andrew J Sanders; Fiona Ruge; Keith G Harding
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

9.  Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis.

Authors:  S K Srivastava; A Bhardwaj; S Arora; N Tyagi; A P Singh; J E Carter; J G Scammell; Ø Fodstad; S Singh
Journal:  Br J Cancer       Date:  2015-05-05       Impact factor: 7.640

10.  Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.

Authors:  Chen Yao; Ying Lin; Mei-Sze Chua; Cai-Sheng Ye; Jiong Bi; Wen Li; Yi-Fan Zhu; Shen-Ming Wang
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

View more
  3 in total

1.  Plasma levels of the proangiogenic protein CXCL16 remains elevated for 1 month after minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Melissa Alvarez Downing; Nipa Dilip Gandhi; Richard L Whelan
Journal:  World J Surg Oncol       Date:  2018-07-07       Impact factor: 2.754

2.  Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; Poppy Addison; Dasuni N Gamage; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Richard L Whelan
Journal:  Mol Clin Oncol       Date:  2021-12-08

Review 3.  The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma-Recent Findings and Review.

Authors:  Jędrzej Borowczak; Krzysztof Szczerbowski; Mateusz Maniewski; Adam Kowalewski; Marlena Janiczek-Polewska; Anna Szylberg; Andrzej Marszałek; Łukasz Szylberg
Journal:  Biomedicines       Date:  2022-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.